Table 3.
Conductance catheterization
| sham + vehicle | sham + dapa | sham + T-1095 | MI + vehicle | MI + dapa | MI + T-1095 | |
|---|---|---|---|---|---|---|
| N | 5 | 6 | 4 | 20 | 13 | 13 |
| EDP (mmHg) | 11 ± 2 | 12 ± 1 | 16 ± 2* | 18 ± 1* | 19 ± 1*‡ | 26 ± 2*† |
| Pes (mmHg) | 117 ± 11 | 127 ± 7 | 127 ± 15 | 107 ± 5 | 105 ± 5 | 95 ± 5* |
| HR (bpm) | 296 ± 12 | 288 ± 12 | 299 ± 11 | 270 ± 7* | 258 ± 6* | 260 ± 9* |
| dP/dtmax (mmHg/s) | 7031 ± 426 | 7471 ± 514 | 7815 ± 504 | 5443 ± 305* | 5141 ± 249* | 4201 ± 264*†‡ |
| dP/dtmin (mmHg/s) | − 7190 ± 631 | − 7922 ± 637 | − 8927 ± 906* | − 4318 ± 260* | − 4192 ± 224* | − 3290 ± 246*†‡ |
| EDPVR (mmHg/ml) | 0.024 ± 0.004 | 0.025 ± 0.002 | 0.03 ± 0.01 | 0.06 ± 0.01 | 0.05 ± 0.01 | 0.10 ± 0.02*†‡ |
| Tau (ms) | 12.5 ± 0.6 | 12.6 ± 0.8 | 12.5 ± 0.7 | 17.5 ± 0.6* | 18.0 ± 0.5* | 23.2 ± 1.6*†‡ |
EDP end-diastolic pressure, Pes end-systolic pressure, HR heart rate, EDPVR end-diastolic pressure volume relationship, ESPVR end-systolic pressure volume relationship
* p < 0.05 vs. sham + vehicle group; † p < 0.05 vs. MI + vehicle group; ‡ p < 0.05 vs. MI + dapagliflozin group